Graft versus host disease

This study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…

This study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …

This study tested a new drug, TQ05105, in 13 people who had severe graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to steroids. The goal was to see if the drug is safe and can help control the disease. The study was stopped early, so results are…

This phase II trial tested whether the drug ibrutinib could prevent chronic graft-versus-host disease (GVHD) in adults who had received a donor stem cell transplant. Only 2 people enrolled before the study was terminated early. Because of the very small number of participants, no…

This trial tested a treatment made from placenta cells (called decidua stroma cells) in 12 adults who had severe graft-versus-host disease (GVHD) after a stem cell transplant and did not respond to steroids. Patients received two doses of the cells or the best available standard …

This study tested a mix of drugs (cyclophosphamide, sirolimus, low-dose IL-2, and azacitidine) to treat severe graft-versus-host disease that didn't respond to steroids. Only 3 patients were enrolled before the trial was stopped early. The goal was to see if the treatment could c…

This study tested a combination of three drugs (ruxolitinib, uhCG/EGF, and steroids) in 10 people with a severe form of acute graft-versus-host disease (aGVHD), a complication that can occur after a stem cell transplant. The goal was to find the lowest effective steroid dose to r…

This pilot study tested whether the drug ruxolitinib could be used as the first treatment for chronic graft-versus-host disease (cGVHD) in children and young adults, instead of the usual high-dose steroids. The goal was to see if it could control the disease while avoiding steroi…

This early-phase study tested whether a special type of cell (interferon gamma-primed mesenchymal stromal cells) could be safely given to prevent graft-versus-host disease, a common and serious complication after bone marrow transplant. Only 4 patients with acute leukemia or myel…

This study tested a new eye drop (rhPRG4) in 3 adults with moderate to severe dry eye from chronic graft-versus-host disease (GVHD), a complication of bone marrow transplants. The goal was to see if the drops safely improve dryness and eye surface damage. The trial was terminated…

This study tested whether shining a special UV light inside the mouth could help people with painful mouth sores caused by graft-versus-host disease after a stem cell transplant. Only 11 people took part, and the study was stopped early. The goal was to see if the light treatment…

This study tested a drug called fostamatinib to help people whose blood cell counts drop after a stem cell transplant. The goal was to see if the drug could raise red blood cells or platelets without needing transfusions. The trial was stopped early after enrolling only one perso…

This study tested a drug called itacitinib combined with steroids to treat acute graft-versus-host disease (aGVHD) in children. aGVHD is a serious complication where donor immune cells attack the child's body after a stem cell transplant. The trial was stopped early after enrolli…

This early-phase trial tested whether adding the drug itacitinib to standard immune-suppressing medications could help prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. The study enrolled 84 participants with leukemia, lymphoma,…

This study tested whether adding itacitinib (an anti-inflammatory drug) to standard steroid treatment could help people with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. The trial enrolled 155 participants but was termi…

This Phase 2 trial tested apraglutide, a drug that helps repair the gut lining, in 31 people with severe gastrointestinal graft-versus-host disease (GVHD) after a stem cell transplant. Participants had GVHD that did not respond to steroids. The study aimed to see if apraglutide i…

This study tested a drug called Cytotect, which contains antibodies against the CMV virus, to prevent CMV infection in people who had a stem cell transplant and developed graft-versus-host disease (GVHD). These patients are at high risk for CMV, and current antiviral drugs often …

This study tested leflunomide, a drug used for rheumatoid arthritis, as a first-line treatment for musculoskeletal graft-versus-host disease (GVHD), a complication of bone marrow transplants where donor cells attack the patient's muscles and joints. The goal was to see if lefluno…

This study tested a new imaging tool called multispectral optoacoustic tomography (MSOT) to see if it could safely detect inflammation in people with graft-versus-host disease, Crohn's disease, or colitis. The device uses light and sound to create images of inflamed areas. The tr…

This pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…

This study tested a monthly solution called Tangible Boost that is meant to restore a special coating on contact lenses. The goal was to see if it could improve comfort and vision in people with severe dry eye from Stevens-Johnson syndrome, Sjogren's syndrome, or graft-versus-hos…

This study looked at how extracorporeal photopheresis (ECP) — a treatment that uses light to modify a patient's own blood cells — affects the immune system in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Only 8 people were en…